Lexicon Pharmaceuticals, Inc. (LXRX)

1,7350 -0,0150 (-0,86%) In data: 11:11AM EDT. Mercato aperto.

Lexicon Pharmaceuticals, Inc.

2445 Technology Forest Boulevard
11th Floor
The Woodlands, TX 77381
United States
281 863 3000
https://www.lexpharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 285

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Lonnel Coats	CEO & Director	1,14M	N/D	1965
Mr. Jeffrey L. Wade J.D.	President & CFO	752,05k	N/D	1965
Mr. Brian T. Crum	Senior VP, General Counsel & Secretary	596,48k	N/D	1973
Dr. Alan J. Main Ph.D.	Executive Vice President of Innovation & Chemical Sciences	576,96k	N/D	1954
Dr. Craig B. Granowitz M.D., Ph.D.	Senior VP & Chief Medical Officer	652,48k	N/D	1965
Ms. Kristen L. Alexander	Vice President of Finance & Accounting	N/D	N/D	1968
Ms. Lisa M. DeFrancesco	Head of Investor Relations & Corporate Strategy	N/D	N/D	1980
Mr. Dixon Terry	Vice President of Compliance	N/D	N/D	N/D
Ms. Carrie Siragusa	Vice President of Marketing	N/D	N/D	N/D
Ms. Desiree Gendron	Vice President of Sales & Training	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Governance aziendale

L'ISS Governance QualityScore di Lexicon Pharmaceuticals, Inc. al 1 giugno 2024 è 9. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 10; diritti degli azionisti: 9; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.